Compare RAVE & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | NSRX |
|---|---|---|
| Founded | 1958 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.5M | 38.9M |
| IPO Year | 1995 | N/A |
| Metric | RAVE | NSRX |
|---|---|---|
| Price | $3.16 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 41.3K | 11.6K |
| Earning Date | 05-07-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $15,120,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.25 | $1.98 |
| 52 Week High | $3.75 | $9.99 |
| Indicator | RAVE | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 50.48 |
| Support Level | $3.07 | $2.78 |
| Resistance Level | $3.48 | $3.60 |
| Average True Range (ATR) | 0.15 | 0.21 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 25.30 | 44.60 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.